Lung cancer: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• EGFR 300
• PD-L1 162
• PD-1 156
• KRAS 98
• ALK 72
• TP53 10
• HER2 63
• MET 43
• PI3K 1
• STAT3 0
• AKT 2
• ROS1 27
• mTOR 0
• VEGF 23
• BRAF 9
• RET 9
• NRF2 1
• MAPK 1
• ERK 0
• STING 0
• STK11 7
• YAP 1
• DLL3 27
• CTLA-4 15
• RAS 15
• CTNNB1 0
• TROP2 13
• JAK 1
• HIF-1 1
• AMPK 0
• PARP 2
• KEAP1 5
• JNK 0
• MYC 1
• B7-H3 14
• GPX4 0
• HER3 11
• PTEN 4
• MEK 1
• TIGIT 6
• FGFR 3
• IL-6 1
• PPAR 0
• EZH2 2
• HDAC 0
• PRMT5 7
• FAK 0
• COX-2 0
• HMGB1 0
• NTRK 5
• AXL 3
• BCL-2 0
• CDK4/6 4
• CXCR4 1
• CD47 1
• METTL3 0
• NLRP3 0
• SHP2 0
• HSP90 0
• MDM2 1

24 of 64+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Designing Programmable MOF-nanocomposites for Synergistic, Redox-Driven Antitumor Therapies (Photo-bioMOF)

  Fundacion IMDEA Energia· Mostoles Madrid, Spain· EU contribution €262,393· until Feb 2030· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Identifying and disrupting neuroimmune circuits in cancer (NeuroCAN)

  Universitat Basel· Basel, Switzerland· EU contribution €1,874,590· until Jun 2032

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Predicting immunotherapy response in melanoma and non-small cell lung cancer patients using an extracellular vesicle-derived miRNA signature and a non-invasive CRISPR-based detection assay. (IT-PREDICT)

  Centre Georges-Francois Leclerc Association· Dijon, France· EU contribution €242,261· until Mar 2029

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  A Dual Amplification Photoelectrochemical Platform for KRAS Mutation Detection (PEAKRAS)

  Universiteit Antwerpen· Antwerpen, Belgium· EU contribution €216,240· until Jan 2029

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  KRAS Targeting in Oncogenic Systems: reconstructing the KRAS signalling network to identify optimal drug combinations (KRATOS)

  University College Dublin, National University of Ireland, Dublin· Dublin, Ireland· EU contribution €426,534· until Jan 2030· 2 countries

  The disease is named only in the funder's project summary, not in the title.

5 of 66 running projects, newest first. Listed amounts together: €224.7m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Suspended

  A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 20 Mutations

  NCT05378763· Spectrum Pharmaceuticals, Inc· Updated 28 Oct 2026

  “The study has not enrolled any patients. The study design is under discussion and will likely be redesigned in consultation with the FDA.”Registry text, quoted unchanged. Source

• Withdrawn

  A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer

  NCT07428044· Memorial Sloan Kettering Cancer Center· Updated 20 Oct 2026

  “sponsor closed study”Registry text, quoted unchanged. Source

• Terminated

  Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors

  NCT06714617· SystImmune Inc.· Updated 22 Sept 2026

  “The decision is based only on the Sponsor's internal portfolio prioritization and resource management considerations and is not due to the investigational product's toxicity considerations.”Registry text, quoted unchanged. Source

• Terminated

  A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2

  NCT05514717· Day One Biopharmaceuticals, Inc.· Updated 18 Jun 2026

  “Development discontinued.”Registry text, quoted unchanged. Source

• Terminated

  Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC

  NCT03066206· M.D. Anderson Cancer Center· Updated 20 Feb 2026

  “\<75% participation”Registry text, quoted unchanged. Source

• Terminated

  A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer

  NCT04982926· Taiho Oncology, Inc.· Updated 14 Oct 2025

  “After careful review of Taiho's ongoing portfolio and data obtained so far in the context of broader landscape of clinical development in NSCLC HER2mut, Sponsor has made a strategic decision to terminate this study and not based on safety concerns.”Registry text, quoted unchanged. Source

• Terminated

  A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors

  NCT04278144· Bolt Biotherapeutics, Inc.· Updated 15 Sept 2025

  “Sponsor Decision”Registry text, quoted unchanged. Source

• Terminated

  DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer

  NCT03505710· Daiichi Sankyo· Updated 30 May 2025

  “Last participant transitioned to alternative study.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• An international study evaluating diagnostic and theranostic agents in patients with solid tumors and brain metastases.

  2025-523824-39-01· Medica Scientia Innovation Research S.L.· Source

• Real-world Outcome of Zongertinib in Japan (J-HERZ)

  NCT07926308· Boehringer Ingelheim· Source

• A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

  NCT06695845· Jazz Pharmaceuticals· Source

• Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

  NCT07195695· Boehringer Ingelheim· Source

• A Study of Mobocertinib in Japanese Adults With Non-Small Cell Lung Cancer

  NCT03807778· Takeda· Source

• A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer

  NCT02716116· Takeda· Source

• Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

  NCT06899126· Daiichi Sankyo· Source

• A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations

  NCT05048797· AstraZeneca· Source

• A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer

  NCT07428044· Memorial Sloan Kettering Cancer Center· Source

• Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

  NCT06625775· TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 145
• Organoids 47
• Mendelian Randomization Analysis 66
• CRISPR-Cas Systems 43
• Gene Expression Profiling 314
• Sequence Analysis, RNA 43
• Whole Genome Sequencing 13
• Exome Sequencing 18
• Proteomics 133
• Metabolomics 67
• Mass Spectrometry 25
• Flow Cytometry 73
• Immunohistochemistry 191
• Liquid Biopsy 76
• Circulating Tumor DNA 83
• Xenograft Model Antitumor Assays 617
• Positron-Emission Tomography 70
• Magnetic Resonance Imaging 116
• Machine Learning 290
• Deep Learning 211
• Cohort Studies 289
• Genome-Wide Association Study 75

• Integrated Whole-Genome and RNA Sequencing Analysis of FFPE Lung Cancer Samples: Feasibility and Pathological Validation.

  Pathol Int, Nov 2026

• Network-informed deconvolution of bulk immune gene co-expression reveals single-cell programs and spatial organization.

  Front Immunol, Sept 2026

• 5' Rapid Amplification of cDNA Ends (5' RACE)-Based Targeted RNA Sequencing Assay for the Analysis of Clinically Relevant Alterations in Lung Cancer Patients.

  Int J Mol Sci, Aug 2026

• Regulatory effects of smoking cessation on the cellular microenvironment and differentially expressed genes in precancerous lesions of pulmonary nodules in mice based on single-cell RNA sequencing and immune repertoire-sequencing.

  PLoS One, Aug 2026

• DeMixNB: deconvolution of sparse-count RNA sequencing data for tumor cells using embedded negative binomial distributions.

  Genome Biol, Aug 2026

• A Rho GTPase-related gene signature predicts prognosis and reveals an immunosuppressive microenvironment in lung adenocarcinoma: an integrated analysis of bulk and single-cell RNA sequencing data.

  Sci Rep, Jul 2026

• PLNFGL: joint estimation of multi-condition gene networks from single-cell RNA-seq data.

  Bioinformatics, Jul 2026

• Unveiling tumor heterogeneity by single cell RNA-sequencing: From basic considerations to clinical applications.

  Semin Cancer Biol, Jun 2026

• ScQCenrich enables multi-metric quality control for single-cell RNA sequencing.

  Commun Biol, Jun 2026

• Single cell RNA-sequencing meta-analysis identifies the molecular signature of smoking cessation on the human lung.

  Transl Res, Jun 2026

See which targets of this disease your abstract mentions, and go to the people working on them.